The ECOG-ACRIN Cancer Research Group is a multidisciplinary, membership-based scientific organization that designs and conducts biomarker-driven cancer research involving adults who have or are at risk of developing cancer. The Group is dedicated to its stated purpose, which is to achieve research advances in all aspects of cancer care and thereby reduce the burden of cancer and improve the quality of life and survival in patients with cancer.
ECOG-ACRIN consists of a headquarters location in Philadelphia and several fully staffed centers and offices. Together, personnel at these facilities oversee the governance, operations, membership, and scientific programs of the Group.
There are nearly 1200 member institutions in the U.S. and around the world. Approximately 12,000 physicians, translational scientists, and associated research professionals from the member institutions are involved in Group research, along with patient representative members who bring the patient voice to the development of ECOG-ACRIN science. Group research is organized into three scientific programs: Cancer Control and Outcomes, Therapeutic Studies and Biomarker Sciences. ECOG-ACRIN is supported primarily through research grant funding from the National Cancer Institute, but also receives funding from private sector organizations through philanthropy and collaborations. PrECOG LLC, a not-for-profit company that partners with ECOG-ACRIN and industry to develop and conduct clinical trials in all areas of oncology.
The Group was formed in May 2012 by a merger that combined the complementary strengths of the Eastern Cooperative Oncology Group (ECOG) in cancer therapy and the American College of Radiology Imaging Network (ACRIN) in cancer imaging. ECOG and ACRIN were two highly respected National Cancer Institute-sponsored cancer cooperative groups. ECOG’s large-scale cancer treatment clinical trials changed the standard of care in numerous types of cancer and helped to individualize cancer therapy. ACRIN’s clinical trials encompassed the full range of medical imaging research, including the investigation of surveillance strategies in high-risk populations, imaging biomarkers in early phase trials, prevention approaches in landmark cancer screening trials, and methodologies in comparative-effectiveness research.
Because of its multidisciplinary membership, ECOG-ACRIN is able to boldly integrate therapeutic and medical imaging research with the latest bioinformatic technologies into a single scientific organization capable of redefining the approach to cancer research and care. To that end, laboratory researchers focused on genetics, targeted therapy, and biomarkers now have access to the best and newest technologies in functional imaging. With its capacity to explore integral biomarkers, including imaging markers of prognosis and response, ECOG-ACRIN is poised to achieve research breakthroughs in all aspects of cancer care.